17th International Conference on Pharmaceutical Medicine
- PDF / 204,511 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 99 Downloads / 263 Views
MEETING REPORT
17th International Conference on Pharmaceutical Medicine 20–21 March 2014; Berlin, Germany Sue Pochon
Published online: 16 October 2014 Ó Springer International Publishing Switzerland 2014
1 Introduction This year marked the 17th International Conference on Pharmaceutical Medicine (ICPM), a bi-annual event organised by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) and the local pharmaceutical medicine society. This year that honour fell to the German Society for Pharmaceutical Medicine—the Deutsche Gesellschaft fu¨r Pharmazeutische Medizin e.V. (DGPharMed)—who also celebrated their 30th annual meeting. Some 350 delegates from 20 countries attended the meeting, which took place in Berlin, Germany, in March, and covered key topics in drug development from a European and global perspective, and combined educational and networking opportunities over the 2-day programme. The theme for this year’s meeting was ‘Smart Development for Better Drugs’, and the importance of training and education of investigators, study personnel and Ethics Committee members was a noticeable common theme throughout the conference. This report offers a brief overview of some of the presentations available to conference attendees.
2 Welcome Address The opening address was given by Dr. Yil-Seob Lee, departing President of IFAPP, who welcomed the delegates and charged them with promoting the speciality and S. Pochon (&) Adis, 5 The Warehouse Way, Northcote, Auckland 0627, New Zealand e-mail: [email protected]
understanding of pharmaceutical medicine, which in some regions is still quite low. Dr. Lee thanked those who had been involved in developing the core competencies for pharmaceutical physicians, which have now been accepted and endorsed by the IFAPP National Member Associations [1]. Efforts will now switch to implementation. Dr. Lee reminded the attendees that IFAPP is changing its organisational structure in order to strengthen the community and improve communication between IFAPP and its National Member Associations, as well as to bring more value to and closer ties with those associations. A new constitution has been endorsed and they are now moving to the next step. Dr. Lee closed his address by telling the delegates that, as specialists, we need to take leadership in pharmaceutical medicine to improve drug development. Dr. Axel Mescheder, President of DGPharMed, welcomed the first keynote speaker of ICPM 2014, Dr. Bernard Munos from the US-based InnoThink Center for Research in Biomedical Innovation.
3 The Globalisation of High-Impact Clinical Research Dr. Munos opened his presentation by reiterating widelyheld concerns about pharmaceutical innovation, with many companies seeing dwindling revenues after years of lacklustre research and development (R&D) productivity. The dearth of new products in the market, especially new successful products, is starting to limit how much money companies can spend on R&D and this is a concern as limiting the amount
Data Loading...
